Kyverna Therapeutics, Inc. Common Stock
KYTXKyverna Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies for the treatment of autoimmune diseases. Leveraging its proprietary gene editing and cellular engineering technologies, Kyverna aims to create treatments that modulate immune responses and improve patient outcomes in conditions such as lupus and other autoimmune disorders.
Company News
The biotech sector rebounded strongly in 2025 as M&A activity surged, becoming a stabilizing force for small and mid-cap companies. With 57% of biopharma acquisitions involving smaller firms and $30.9 billion in deals, investor sentiment shifted from GLP-1 drugs toward cancer and autoimmune disease treatments, particularly next-generation CAR-T t...
Kyverna Therapeutics, a clinical-stage biopharmaceutical company, has priced a public offering of 13,333,333 shares at $7.50 per share, expecting to raise approximately $100 million to support its cell therapy development for autoimmune diseases.
U.S. stock markets experienced a slight decline on December 15, 2025, with the S&P 500, Nasdaq, and Dow Jones showing modest losses as investors await economic data and potential Federal Reserve rate decisions.
Kyverna Therapeutics will host a conference call to discuss topline results from its Phase 2 clinical trial of KYV-101, a CD19 CAR T-cell therapy targeting stiff person syndrome, with potential for durable disease-free remission.
The diffuse cutaneous systemic sclerosis (dcSSc) market is evolving towards targeted therapies addressing fibrosis and immune modulation, with promising drug candidates from multiple pharmaceutical companies targeting various pathogenic pathways.
